Jacob Trefethen, who leads life sciences at the OpenAI Foundation, speaks to Nature about the organization’s ambitions to cure disease.

I started this blog in February 2024, with a post about February 2029. Reviewing at the halfway point: nine of the ten technologies I wrote about are still unavailable, and we're not close on most of ...

Hard Drugs · Episode

At Open Philanthropy, we have given away $600 million in biomedical research since 2016. That funding has supported the work of thousands of scientists across hundreds of universities, nonprofits, and...

Some say AI will solve medicine within a decade. Others believe biology is far more complex than people imagine and AI will hit the limits of clinical trials and economics. Who's right?

Rapid AI progress does not automatically mean rapid medical progress. If the point of AI progress is human flourishing, we must make other complementary investments too. Even with extremely powerful A...

We are excited to announce the launch of our new Abundance and Growth Fund, which will spend at least $120 million over the next three years to accelerate economic growth and boost scientific and tech...

In the 1980s, many thought tuberculosis was on the path to elimination. In reality, more were dying from the disease than ever.

Gilead’s twice-a-year HIV prevention drug lenacapavir is 30 years in the making. Here’s the story behind it. https://www.statnews.com/2025/06/23/fda-approval-lenacapavir-yeztugo-gilead-history-development-breakthrough-william-pao/?utm_source=bluesky&utm_campaign=bluesky_organic&utm_medium=social

Podcast · Saloni Dattani & Jacob Trefethen · Hard Drugs is a show by Saloni Dattani and Jacob Trefethen about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesavin...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the current political climate.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.